

An Intronic G Run within HIV-1 Intron 2 Is Critical for Splicing Regulation of *vif* mRNA

Marek Widera,^a Steffen Erkelenz,^a Frank Hillebrand,^a Aikaterini Krikoni,^b Darius Widera,^c Wolfgang Kaisers,^e René Deenen,^e Michael Gombert,^d Rafael Dellen,^{e,f} Tanya Pfeiffer,^h Barbara Kaltschmidt,^g Carsten Münk,^b Valerie Bosch,^h Karl Köhrer,^e Heiner Schaal^a

Institute for Virology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany^a; Clinic for Gastroenterology, Hepatology, and Infectiology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany^b; Cell Biology, University of Bielefeld, Bielefeld, Germany^c; Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany^d; Biological and Medical Research Center (BMFZ), Heinrich Heine University Düsseldorf, Düsseldorf, Germany^e; Institute for Computer Science, Heinrich Heine University Düsseldorf, Düsseldorf, Germany^f; Molecular Neurobiology, University of Bielefeld, Bielefeld, Germany^g; Forschungsschwerpunkt Infektion und Krebs, Deutsches Krebsforschungszentrum, Heidelberg, Germany^h

Within target T lymphocytes, human immunodeficiency virus type I (HIV-1) encounters the retroviral restriction factor APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; A3G), which is counteracted by the HIV-1 accessory protein Vif. Vif is encoded by intron-containing viral RNAs that are generated by splicing at 3' splice site (3'ss) A1 but lack splicing at 5'ss D2, which results in the retention of a large downstream intron. Hence, the extents of activation of 3'ss A1 and repression of D2, respectively, determine the levels of *vif* mRNA and thus the ability to evade A3G-mediated antiviral effects. The use of 3'ss A1 can be enhanced or repressed by splicing regulatory elements that control the recognition of downstream 5'ss D2. Here we show that an intronic G run (G_{12-1}) represses the use of a second 5'ss, termed D2b, that is embedded within intron 2 and, as determined by RNA deep-sequencing analysis, is normally inefficiently used. Mutations of G_{12-1} and activation of D2b led to the generation of transcripts coding for Gp41 and Rev protein isoforms but primarily led to considerable upregulation of *vif* mRNA expression. We further demonstrate, however, that higher levels of Vif protein are actually detrimental to viral replication in A3G-expressing T cell lines but not in A3G-deficient cells. These observations suggest that an appropriate ratio of Vif-to-A3G protein levels is required for optimal virus replication and that part of Vif level regulation is effected by the novel G run identified here.

Replication of human immunodeficiency virus type 1 (HIV-1) is counteracted by four major classes of host-encoded restriction factors: APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; A3G), TRIM5 α (tripartite motif 5 α), tetherin (BST-2, CD317, or HM1.24), and SAMHD1 (1–4). A3G (5) belongs to a family of cytidine deaminases that includes seven members (A3A to A3D and A3F to A3H) located in a gene cluster on chromosome 22 (6–8). It is encapsidated into newly assembled virions and introduces C-to-U substitutions during minus-strand synthesis, resulting in G-to-A hypermutations and aberrant DNA ends in the HIV-1 genome. Furthermore, A3G, independent of its deaminase activity, inhibits reverse transcriptase-mediated minus-strand elongation by direct binding to the viral RNA (9). This leads to massive impairment of viral replication (10). However, the HIV-1-encoded accessory protein Vif counteracts A3G by direct interaction, by inducing proteasomal degradation, and by repression of mRNA synthesis (10). Whereas HIV-1 is able to replicate efficiently in A3G-expressing cells, Vif-deficient virus strains are completely suppressed (5). Nevertheless, a narrowly restricted level of Vif is crucial for optimal HIV-1 replication since proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site is inhibited by high levels of Vif (11).

During the course of infection, the HIV-1 9-kb single-sense pre-mRNA is processed into more than 40 alternatively spliced mRNA isoforms encoding 18 HIV-1 proteins, all of which interact with a wide variety of host cell proteins, complexes, and pathways (12). Furthermore, negative-sense mRNAs that lead to the expression of at least one antisense protein are also found in HIV-1-infected T cells (13).

The splicing process consists of a series of consecutive steps that are orchestrated by interactions of individual spliceosomal components (14). The initial binding of the U1 snRNP to the pre-mRNA is mediated by base pairing between the 5' end of the U1 snRNA and the 5' splice site (5'ss) initiating early E-complex formation (15). Subsequently, the 3'ss, consisting of the AG dinucleotide, the branch point sequence (BPS), and a polypyrimidine tract, is bound by the U2 snRNP at the BPS in an ATP-dependent manner, thus initiating A-complex formation. In a process named exon definition, U1 and U2 snRNPs bound to the exon-intron borders pair with each other (cross-exon interactions) and facilitate the removal of the flanking introns (16, 17).

Rev expression initiates the switch from the early to the late stage of viral replication (18). On binding to the Rev-responsive element (RRE), Rev oligomerizes cooperatively and, by interacting with the cellular Crm1 export pathway, facilitates the export of intron-containing viral mRNAs (19–21).

Since the *vif* AUG is localized within intron 2, this intron must be retained within the functional *vif* mRNA. Thus, the 5'ss D2 has to be rendered splicing incompetent, even though binding of U1 snRNP to this 5'ss is a prerequisite for efficient recognition of the upstream 3'ss A1 (22, 23). In general, 5'ss splice donor repression

Received 4 October 2012 Accepted 13 December 2012

Published ahead of print 19 December 2012

Address correspondence to Heiner Schaal, schaal@uni-duesseldorf.de.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JVI.02755-12

may be a common requirement for the generation of all spliced but intron-containing HIV-1 mRNAs, e.g., the *env* mRNAs (24). Indeed, recent studies demonstrated that the splicing regulatory element (SRE)-mediated binding of the U1 snRNP to a 5' splice site does not necessarily result in its processing into the spliceosomal A-complex formation but can lead to a "dead-end" complex formation that prevents the splicing process (25–28).

Comparative analyses of the intrinsic strengths of all HIV-1 3' splice sites have shown that A1 is intrinsically inefficient (18) and, in the absence of other effects, would result in *vif* mRNA species representing only ~1% of the total 4.0-kb mRNA class (29). However, in the presence of its downstream exonic sequence, A1 switches from being intrinsically very weak to being the most active HIV-1 3' splice site (18). Indeed, two SREs within the noncoding leader exon 2 have been reported to enhance its splice site recognition, the SRSF1 (SF2/ASF)-dependent heptameric exonic splicing enhancers (ESEs) M1 and M2 (18) and the SRSF4 (SRp75)-dependent ESE Vif (22). Only the GGGG silencer element, which overlaps D2, is known to negatively act on exon 2 inclusion and *vif* mRNA production (22).

G runs (DGGGD, where D is U, G, or A) belong to those sequence motifs known to be bound by hnRNPs F and H (30) and often act as regulators within a variety of genes by modulating their splice site usage (30–38). Their influence is positive when they are localized immediately downstream of the 5' splice site (39–43) or, alternatively, when multiple copies are present even further downstream (44–46).

It has been shown that overexpression of hnRNP F and H reduces the levels of HIV-1 transcripts by approximately 60% (hnRNP F) and 30% (hnRNP H) and affects the splicing pattern by increasing the relative amount of exon 3-containing mRNAs that splice to 3' splice site A2 (Nef4, Env8, Vpr3, and Rev7/8/9). In line with this, knockdown of these splicing factors with small interfering RNA shows an inverse effect and results in mRNAs in which exon 3 skips, indicating that these proteins drive splicing toward 3' splice site A2 (47, 48). Similarly, the ESS2p silencer downstream of 3' splice site A3 (49) and the interaction of U1 snRNP with exon 6D 5' splice site are regulated by hnRNPs F and H (50). Furthermore, in a subgenomic splicing reporter, the S3 G run in HIV-1 exon 1 was shown to modulate HIV-1 splicing by hnRNP H proteins (30). However, within a proviral context, the S3 G-run activity could not be confirmed (51).

Since there are many additional G runs present throughout the HIV-1 genome that might act as binding sites for hnRNP F/H family members, we sought to functionally analyze the impact of all of the G runs within the *vif* AUG-containing intron on the processing of the *vif* mRNA. We found that the G run localized directly upstream of the *vif* AUG was bound by members of the hnRNP F/H family and that binding was necessary for the maintenance of physiological *vif* mRNA levels.

MATERIALS AND METHODS

Plasmids. The HIV-1 NL4-3 (GenBank accession no. M19921)-derived plasmid long terminal repeat (LTR) 4 exon was cloned by inserting the NdeI/EcoRI fragment from pNL4-3 (52) into the previously described LTR ex2 ex3 reporter (53). The minigene construct contains small noncoding leader exons 2 and 3, the 5' part of *tat* exon 1, and the authentic NL4-3 full-length sequences for introns 2 and 3 in between. The coding regions for *gag* and *pol* within intron 1 (44 bp downstream of SD1 and 69 bp upstream of SA1) had been replaced with a short 13-bp linker fragment. LTR 4 exon G₁₂-1 mut was generated by PCR-directed mutagenesis

with primer pair 1544/3307, subsequent digestion with BssHI/NdeI, and ligation into the LTR 4 exon. Cloning of plasmid LTR 4 exon G₁₂-2,3 mut was created by PCR-directed mutagenesis with primers 2339/3306 with LTR 4-exon as the template and subsequent digestion with SacI/PfI and integration into the LTR 4 exon. LTR 4 exon G₁₂-4,5 was generated by amplifying 2710/3441 on the LTR 4 exon with subsequent digestion with NdeI/PfI and ligation into the LTR 4 exon. LTR 4 exon G₁₂-1-5 mut was cloned by using the same primers, 2710/3441; LTR 4 exon G₁₂-4,5 as the PCR template; and integration into LTR 4 exon G₁₂-1 mut with SacI/PfI. To generate HIV-1 molecular clone pNL4-3 G₁₂-1, the intron 1 sequence was extended up to the AgeI restriction site by cloning the PCR amplicon generated with primers 3375/3376 and digestion with EcoRI/NdeI, resulting in LTR 4 exon int1ext and LTR 4 exon int1ext G₁₂-1 mut, respectively. Cloning of pNL4-3 G₁₂-1 was then performed by using the AgeI/EcoRI fragment from LTR 4 exon int1ext G₁₂-1 mut, which was inserted into pNL4-3.

Rev expression plasmids SVcrev4 (4083/4084), SVcrev4b (4085/4086), SVcrev4 eff (4121/4122), and SVcrev4b eff (4123/4124) were cloned by replacement of the EcoRI/SacI fragment from SVcrev (54) with each indicated complementary oligonucleotide mixed at equimolar concentrations. Therefore, each oligonucleotide mixture was heated at 95°C for 5 min, cooled down to room temperature for 1 h, and subjected to DNA ligation. pXGH5 (55) was cotransfected to monitor transfection efficiency in quantitative and semiquantitative reverse transcription (RT)-PCR analyses. For minigene experiments, SVctat (54) was cotransfected to transactivate the HIV-1 LTR promoter. SVtat⁻rev⁻envRL was generated to replace the gene for chloramphenicol acetyltransferase (CAT) with a *Renilla* luciferase gene expression cassette by insertion of the XmaI/BbsI fragment from SVt⁻r⁻envCAT (simian virus 40 [SV40] early promoter, pNL1 sequence nucleotides [nt] 5743 to 8887, tat⁻ [ATG→AGG], rev⁻ ATG→ACG; the sequence coding for Gp120 was replaced with the CAT-encoding gene sequence; SV40 polyadenylation signal) and the Esp3I/XmaI-restricted PCR amplicon (1271/1272) into pRLSV40 (Promega). pGL3-Control (Promega) was cotransfected to monitor transfection efficiency by firefly luciferase expression. All constructs were validated by DNA sequencing.

RNA and protein isolation from transiently transfected and infected cells. HeLa-T4⁺ and HEK 293T cell cultures were prepared with Dulbecco's high-glucose modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum and penicillin and streptomycin each at 50 µg/ml (Invitrogen). Jurkat, CEM-A, CEM-T4, and CEM-SS cells were maintained in RPMI 1640 medium (Invitrogen) under the same conditions. Transient-transfection experiments were performed with six-well plates at 2.5 × 10⁵ cells per plate by using TransIT-LT1 transfection reagent (Mirus Bio LLC) according to the manufacturer's instructions. Total RNA and proteins were isolated by using the AllPrep DNA/RNA/Protein minikit (Qiagen) according to the manufacturer's instructions. Alternatively, total RNA was isolated by using acid guanidinium thiocyanate-phenol-chloroform as described previously (56).

Quantitative and semiquantitative RT-PCRs. For reverse transcription (RT), 5 µg of RNA was digested with 10 U of DNase I (Roche). The DNase was subsequently heat inactivated at 70°C for 5 min, and cDNA synthesis was performed for 1 h at 50°C and 15 min at 72°C by using 200 U Superscript III RNase H reverse transcriptase (Invitrogen), 7.5 pmol oligo(dT)₁₂₋₁₈ (Invitrogen), 20 U of RNasin (Promega), and 10 mM each deoxynucleoside triphosphate (Qiagen). For semiquantitative analysis of minigene and viral mRNAs, cDNA was used as the template for a PCR with the indicated primers. For transfection controls, PCRs were performed with primers 2258 and 2263 to detect spliced GH1 mRNA and with primers 3153 and 3154 for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively. PCR products were separated on 10% non-denaturing polyacrylamide gels, stained with ethidium bromide, and visualized with an F1 Lumi-Imager (Roche). Quantitative RT-PCR analysis was performed by using the LightCycler DNA Master SYBR green I kit (Roche) and LightCycler 1.5 (Roche). For normalization, primers 3387

TABLE 1 DNA oligonucleotides used in this work

Primer	Sequence
1271	5'-AGCAGTCGTCTCGTGGCCAAGAAATGGCTTCGAAAGTTTATGAT-3'
1272	5'-TAGCCCGGGCTACTATTATTGTTTCATTTTTGAGA-3'
1544	5'-CTTGAAAGCGAAAGTAAAGC-3'
2258	5'-TCTTCCAGCCTCCCATCAGCGTTTGG-3'
2263	5'-CAACAGAAATCCAACCTAGAGCTGCT-3'
2339	5'-TGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGC-3'
2588	5'-CTTTACGATGCCATTGGGA-3'
2710	5'-GGGGGATCGATAATTAAGGAGTTTATATGAAACCCTTAAAGGTAAAGGGGCAGTAGTAATACAA-3'
3153	5'-ACCACAGTCCATGCCATCAC-3'
3154	5'-TCCACCACCCTGTTGCTGTA-3'
3306	5'-TTCCTCCATTCTATGGAGACGCCTTGACCCAAATGCCAGTCTCTTTCTCTGTATGCAGACCCCAATATGTTGTTATTACTAATTT AGCATCGCCTAGTGGGATGTGACTTCTG-3'
3307	5'-TATACATATGGTGTGTTTACTAACTTTTCCATGTGTTAATCCTCATCCTGTCTACTTGCCACACAATCATCACCTGCCATCTGTTT TCCATAATCGCGGATGATCTTTGCTTTTCTTCTTGGC-3'
3375	5'-GGCCTGAATTCAGGGAGATTCTAAAAGAACCGGTACAT-3'
3376	5'-TATACATATGGTGTGTTTACTAACTTTTCC-3'
3387	5'-TTGCTCAATGCCACAGCCAT-3'
3388	5'-TTTGACCACTTGCCACCCAT-3'
3392	5'-CGTCCAGATAAGTGCTAAGG-3'
3395	5'-GGCGACTGGGACAGCA-3'
3396	5'-CCTGTCTACTTGCCACAC-3'
3441	5'-TTTCTCCATTCTATGGAGACGCCTTGCCGAGATGCCAGTCTCTTTCTCTGTATGCAGGCCGAAGTATGTTGTTATTACTAATTT AGCATCGCCT-3'
4083	5'-AATTCCTCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCT-3'
4084	5'-CTTCGTCGCTGTCTCCGCTTCTTCTGCCATAGGAGG-3'
4085	5'-AATTCGGATTATGAAAAACAGATGGCAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCT-3'
4086	5'-CTTCGTCGCTGTCTCCGCTTCTTCTGCCATAGGAGATGCCTGCCATCTGTTTTCCATAATCCG-3'
4121	5'-AATTCAGCCATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCT-3'
4122	5'-CTTCGTCGCTGTCTCCGCTTCTTCTGCCATGGCTGG-3'
4123	5'-AATTCAGCCATGAAAAACAGATGGCAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCT-3'
4124	5'-CTTCGTCGCTGTCTCCGCTTCTTCTGCCATAGGAGATGCCTGCCATCTGTTTTCCATGGCTGG-3'
4355	5'-TTCATCGAATTCAGTGCCAAGAAGAAAAGCAAAGATCA-3'

and 3388 were used, detecting all HIV-1 mRNAs. Detection of *vif* mRNA was performed by using primer pair 3395/3396.

Oligonucleotides. All of the DNA and RNA oligonucleotides used in this study were obtained from Metabion (Table 1).

RNA pulldown. Three thousand picomoles of high-performance liquid chromatography-purified RNA oligonucleotides 3600 (GATCATCA GGGATTATGGA [underlining indicates the wild-type 3600 and the mutant 3601 G₁₂-1 sequences]) and 3601 (GATCATCCGCGATTATGGA) was adjusted to a total volume of 340 μ l. Twenty microliters of a saturated sodium metaperiodate solution and 40 μ l of sodium acetate (1 M, pH 5) were added, and after incubation for 1 h at room temperature in the dark, the RNAs were precipitated by the addition of 80 μ l of sodium acetate (1 M, pH 5) and 1 ml of ethanol (96%) and incubation at -80°C for 5 min and subsequently pelleted at full speed for 30 min at 4°C . The RNAs were covalently linked to adipic acid dihydrazide-agarose beads (Sigma) at 4°C overnight and washed twice with sodium chloride (2 M) and three times with Dignam buffer D (20 mM HEPES-KOH [pH 7.6], 6.5% [vol/vol] glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol [DTT]). Two hundred microliters of HeLa cell nuclear extract (~ 6 mg/ml; Cibiotech) was added to the immobilized RNA, and the mixture was incubated for 20 min at 30°C and washed five times with Dignam buffer D plus MgCl_2 (20 mM HEPES-KOH [pH 7.6], 6.5% [vol/vol] glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM DTT, 1 M MgCl_2). Agarose beads were resuspended in 2 \times protein sample buffer (0.75 M Tris-HCl [pH 6.8], 20% [vol/vol] glycerol, 10% [vol/vol] β -mercaptoethanol, 4% [wt/vol] SDS), and the proteins were eluted by heating at 95°C for 10 min and subjected to SDS-PAGE and Coomassie staining.

Immunoblot analysis. Proteins were subjected to SDS-PAGE under denaturing conditions (57) in 12% polyacrylamide gels (Rotiphoresis Gel

30; Roth) using Bio-Rad Protean II Mini electrophoresis systems (Bio-Rad). Gels were run in Laemmli running buffer (1% SDS, 0.25 M Tris base, 1.9 M glycine) for 45 min at 25 mA and 4°C . The proteins were transferred to a polyvinylidene difluoride membrane (pore size, 0.45 μm ; Protran) by using the Bio-Rad Protean II Mini tank blotting system (Bio-Rad) in transfer buffer (0.1% SDS, 192 mM glycine, 25 mM Tris [pH 8.8], 20% methanol). The membrane was washed twice in TBS-T (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% [vol/vol] Tween 20), blocked in TBS-T with 10% nonfat dry milk for 1 h at room temperature, and then incubated overnight at 4°C with the primary antibody in TBS-T with 5% dry milk. Sheep antibody against HIV-1 p24 CA was obtained from Aalto Bioreagents Ltd. (Dublin, Ireland), and rabbit antiserum against Vif was obtained through the NIH AIDS Research and Reference Reagent Program from Dana Gabuzda and Jeffrey Kopp (58). Anti-A3G immunoblot assays were performed with anti-ApoC17 antibody from Klaus Strebel (59, 60). The membrane was washed three times with TBS-T for 10 min each time and incubated with anti-rabbit horseradish peroxidase (HRP)-conjugated antibody (A6154) from Sigma-Aldrich and HRP-conjugated anti-sheep antibody from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA) for 1 h, respectively. The blot was washed four times, rinsed with water, visualized by a ECL chemiluminescence detection system (Amersham), and exposed to photosensitive film (GE) or Lumi-Imager F1 (Roche). Immunoblotting employing the Gp41 monoclonal antibody Chessie 8 (61) was performed as previously described (62). The p24-CA protein in the cell-free supernatant was concentrated by using sucrose centrifugation at $50,000 \times g$ for 4 h and subsequently subjected to immunoblot analysis as described above.

Luciferase measurement. HeLa-T4⁺ cells (2.5×10^5) were transiently transfected with 2 μg SVtat⁻ rev⁻ envRL reporter plasmid, 0.5 μg pGL3-

Control (Promega) for normalization and expression plasmids as indicated and pcDNA3.1 (+) to adjust the amount of transfected DNA to 3.5 μg per sample. For luciferase measurement, cultured cells were rinsed in phosphate-buffered saline (PBS), dispensed into 500 μl passive lysis buffer (Promega), and shaken for 15 min at ambient temperature, and the cell lysates were cleared by centrifugation for 10 s at $20,000 \times g$. Firefly and *Renilla* luciferase activities were measured by a dual-luciferase program by adding 100 μl Beetle-Juice and *Renilla*-Juice (p · j · k) with Mithras LB 940 (Berthold), respectively.

Northern blot analysis. Total RNA (2 μg) was electrophoresed on a denaturing 1% agarose gel and capillary blotted onto a positively charged nylon membrane by using $20\times$ SSC (3 M NaCl, 300 mM sodium citrate). The RNA was UV cross-linked to the membrane, and the large and small rRNAs were marked. Subsequently, the membrane was prehybridized with 10 ml $1\times$ DIG Easy Hyb hybridization solution (Roche) for 1 h at 65°C . The membrane was then hybridized with probes for 5 h at 55°C . The probe for HIV-1 mRNAs was based on a 153-bp digoxigenin (DIG)-labeled PCR product using the primer pair 3387/3388 (HIV-1 exon 7). The PCR product was purified by using phenol and chloroform-isoamyl alcohol (24:1 ratio), and a second PCR was performed by using DIG-labeled dUTPs (alkali-labile DIG-11-dUTP; Roche), the same primer pair, and the first PCR product as the template. The probe was heated in $1\times$ DIG Easy Hyb hybridization solution (Roche) at 95°C for 5 min and chilled on ice. Following overnight hybridization at 55°C , the membranes were washed twice with wash buffer $2\times$ SSC (300 mM NaCl, 30 mM sodium citrate) with 0.1% SDS at room temperature, followed by two 20-min washes in $0.2\times$ SSC (30 mM NaCl, 3 mM sodium citrate) with 0.1% SDS at 68°C . The membrane was then washed twice with double-distilled H_2O and maleic acid buffer (0.1 M maleic acid, 0.15 M NaCl) and blocked with blocking solution (Roche) for 1 h. Alkaline phosphatase (AP)-conjugated anti-DIG-antibody (Fab fragments from sheep antibody; Roche) was diluted 1:20,000 in $1\times$ blocking solution (Roche) and incubated for 1 h. The membrane was washed three times with maleic acid buffer, and the RNA bands were visualized by using CDP-Star for chemiluminescent reactions (1:100 in AP buffer [0.1 M Tris HCl, 0.1 M NaCl, pH 9.5]; Roche).

Measurement of HIV-1 replication kinetics. CEM-A, CEM-T4, and CEM-SS cells (4×10^5) were infected with 1.6 ng p24 CA of wild-type and mutant viruses in serum-free RPMI medium at 37°C for 6 h. Infected cells were then centrifuged, washed in PBS (Invitrogen), and resuspended in RPMI medium (Invitrogen) containing 10% fetal calf serum (FCS; Invitrogen). Aliquots of cell-free medium were harvested at regular intervals, and virus production was measured by p24 enzyme-linked immunosorbent assay (ELISA). Peripheral blood mononuclear cells (PBMCs) were isolated from 15-ml whole-blood samples from two healthy donors by Ficoll gradient centrifugation. PBMCs were cultured in RPMI 1640 GlutaMax medium containing 10% FCS and 1% penicillin-streptomycin, activated with phytohemagglutinin (5 $\mu\text{g}/\text{ml}$), and treated with interleukin-2 (30 mg/ml ; Roche) after 48 h. Cells (8×10^5) were infected with 16 ng of p24 CA of wild-type and mutant viruses and treated as described above.

Next-generation sequencing (NGS) and read mapping. Total RNA was extracted from 5×10^6 Jurkat cells per sample by using the AllPrep DNA/RNA/Protein minikit (Qiagen), and the preparations were checked for RNA integrity with an Agilent 2100 Bioanalyzer. All of the samples in this study showed common high-quality RNA integrity numbers (9.1 to 10; mean, 9.9). RNA was quantified by photometric measurement (NanoDrop 1000 Spectrophotometer, ND-1000 version 3.7.0; Thermo Scientific). Syntheses of cDNA libraries were performed with the TruSeq RNA Sample Prep kit (Illumina) according to the manufacturer's protocol. One microgram of total RNA was used for poly(A) RNA enrichment, followed by cDNA synthesis, adapter ligation, and PCR amplification. The resulting cDNA libraries were validated by Agilent DNA 1000 chip, quantified by fluorometric measurement (Qubit dsDNA HS Assay kit; Invitrogen), and adjusted to 10 nM.

Clonal amplification of cDNA on two Illumina flow cells (v1.5) was done by using the appropriate cBot recipe (version 7) at a final library concentration of 10 pM. Sequencing was carried out on a HiSeq 2000 according to the manufacturer's protocol (HiSeq 2000 User Guide, part 15011190, revision H; Illumina, Inc.) using TruSeq SBS kits v1. The resulting 101-nt sequence reads were converted to fastq by CASAVA 1.8.2. The 101-nt reads were mapped to an exon junction database by using the reference mapping algorithm within the CLC Genomics Workbench software (v4.9; CLC bio). On the basis of those reads mapping to HIV-1 exon junctions, we then estimated relative splice site usage. Read sequences that mapped to more than one exon junction were excluded from quantification. In order to identify unannotated splice events, Reads were mapped with TopHat2.0.0 to HIVNL43 sequence (downloaded from <http://www.ncbi.nlm.nih.gov/nucore/M19921>).

RESULTS

A guanosine (G) run element (G_{12-1}) embedded within HIV-1 intron 2 controls splicing at 5' ss D2b. To analyze whether one of the five G runs identified within HIV-1 intron 2 (G_{12-1-5}) is involved in splice site regulation and processing of *vif* mRNA, we performed a mutational analyses of these motifs (Fig. 1). Using an HIV-1 subgenomic splicing reporter (Fig. 1C), we disrupted the G runs individually or in combination (G_{12-1-5} mut) and determined individual splicing outcomes. For the analysis in the context of infectious provirus, mutations were chosen that did not change the coding sequence of the overlapping IN (integrase) and *Vif* open reading frames (ORFs). Only mutation G_{12-4} resulted in an amino acid substitution (W70F) within the *Vif* protein (Fig. 1D).

Total RNA was isolated 24 h following the transient transfection of HeLa-T4⁺ cells, and the splicing pattern was analyzed by RT-PCR and quantitative RT-PCR (Fig. 2). Mutating G run G_{12-1} , which is highly conserved among most HIV-1 strains and subtypes, although not among HIV-2 nor simian immunodeficiency virus strains (Los Alamos HIV database 2011, data not shown), led to an increased amount of both the exon 2-containing transcript *tat2* (Fig. 2B, 1544/2588, cf. lanes 2 and 3) and the intron 2-retaining *vif2* mRNA (Fig. 2B, 1544/3396, cf. lanes 2 and 3). Additionally, we detected an unknown RT-PCR product migrating slower than *tat3* (Fig. 2B, line 3, [1.2b.4]). Sequencing analysis showed this to be a splicing isoform resulting from splicing at an alternative 5' ss downstream of D2 (Fig. 1D and 2A). This 5' ss, referred to here as D2b, has been described previously as being a rarely detectable cryptic 5' ss at position 5059 (29). Of note, 5' ss D2b has an even slightly stronger intrinsic strength (CAGGTgAtgAT, HBS 12,4/MAXENT 5,99) than D2 (aAGGTgAaggg, HBS 10,7/MAXENT 5,79) (45, 63) and, like G_{12-1} , is remarkably conserved among most HIV-1 strains and subtypes (Los Alamos HIV database 2011, data not shown). Therefore, the efficiency of D2b use would have been expected to be similar to that of D2. In order to confirm splicing at 5' ss D2b in the context of nonmutated pre-mRNAs, HeLa-T4⁺ or HEK 293T cells were transfected with the splicing reporter and splicing patterns analyzed. Indeed, using a 5' primer positioned between D2 and D2b, we could confirm detectable, but weak, D2b usage even in the absence of the G_{12-1} mutation (data not shown). Remarkably, disruption of G_{12-1} also led to the increased activation of 3' ss A1 and *vif* mRNA formation in semiquantitative (Fig. 2B, 1544/3396) and quantitative RT-PCR analyses (Fig. 2C, 3395/3396).

In support of a functionally exclusive role for G_{12-1} in *Vif* splice site regulation, the mutation of any of the other G runs (G_{12-2} , 3




FIG 1 HIV-1 intron 2 contains several G runs and an alternative 5' splice site. The diagram shows the locations of splice sites, exons, introns, and SREs in the HIV-1 NL4-3 genome. (A) Schematic overview of the HIV-1 NL4-3 genome, including the locations of 5' splice sites and 3' splice sites, respectively. The RRE is indicated by an open box. The positions of the PCR primers used in this analysis are indicated by black triangles. (B) *vif* mRNA is formed primarily by splicing of 5' splice site D1 to 3' splice site A1 where noncoding exon 2 (50 nt) is included and *vif* AUG-containing intron 2 is retained. *Rev4* is formed by splicing of 5' splice site D1 to 3' splice site A4b and spliced downstream from 5' splice site D4 to 3' splice site A7. In contrast, *rev4b* is formed by splicing from alternative 5' splice site D2b to 3' splice site A4b up, taking the *vif* AUG into the *rev* ORF. (C) *Vif*-coding intron 2 sequence (427 nt) including the locations of the *vif* ATG and G run G₁₂-1. The intrinsic strengths of 5' splice sites D2 and D2b are indicated (HBS, MAXENT). (D) Representation of the mutant constructs used in this work. The mutant constructs were based on the reference sequence from infectious proviral clone NL4-3. With the exception of G₁₂-4, silent mutations were introduced to maintain the coding sequence for the amino acids of integrase and *Vif*. G₁₂-4 led to a tryptophan-to-phenylalanine amino acid substitution in the *vif* ORF. (E) Amino acid sequences for *Gp41a*, *Gp41b*, and *Rev4b* mRNAs.

and G₁₂-4, 5) did not affect the splicing pattern of the splicing reporter.

Members of the hnRNP F/H protein family bind to the intronic G run (G₁₂-1). Since G-run motifs have been shown to bind

members of the hnRNP F/H protein family, RNA affinity purification assays were performed to determine if this were also the case with the viral G₁₂-1 sequence. RNA oligonucleotides containing the wild-type or mutant G₁₂-1 sequence were immobilized on




FIG 2 Alternative 5' splice sites within HIV-1 NL4-3 intron 2 leads to alternative transcript isoforms. (A) Schematic drawing of the HIV-1 pNL4-3-derived subgenomic splicing reporter (LTR 4 exon). The reporter contains noncoding leader exons 2 and 3 flanked by authentic NL4-3 sequences. Coding regions for *gag* and *pol* in intron 1 have been deleted and replaced with a shorter linker sequence (see Materials and Methods). The 5' splice sites and 3' splice sites, including D2b, are indicated. The positions of the RT-PCR primers used are depicted by arrows. (B) RT-PCR analysis of total RNA isolated from HeLa-T4⁺ cells transiently transfected with the subgenomic splicing reporter shown in panel A or its mutant derivative at 24 h posttransfection. Cells were cotransfected with SVcat and pXGH5 (GH1). The primer pairs used are indicated on the left (see panel A). Every band was isolated from the gel and confirmed by sequencing analysis. Transcript isoforms are depicted on the right. To compare the total RNA amount and transfection efficiency, a separate RT-PCR was performed by using primer pair 2263/2858 to amplify a spliced GH1 sequence. PCR amplicons were separated on a nondenaturing 10% polyacrylamide gel and stained with ethidium bromide. (C) Quantitative RT-PCR of total RNA from panel B using exon junction primers specific for *vif*mRNA (3395/3396). The authentic splice pattern (wt) was set to 100%. The relative splice site usage was normalized to cotransfected GH1.

agarose beads and incubated with HeLa cell nuclear extract. Bound proteins were eluted and separated by SDS-PAGE (Fig. 3). Protein bands bound to the wild-type G_{12-1} oligonucleotide but exhibiting less efficient binding to the mutant G_{12-1} RNA oligonucleotide were analyzed by mass spectrometry. These analyses




FIG 3 Proteins hnRNP F, hnRNP H, and hnRNP A2/B1 bind to the intronic G run (G_{12-1}) but not to the mutated sequence. Shown is a Coomassie-stained protein gel of a G_{12-1} RNA pulldown experiment. Short (19-nt) RNA oligonucleotides (wt, GATCATCAGGGATTATGGA; G_{12-1} mut, GATCATCCGCGA TTATGGA) of authentic or mutated G_{12-1} sequence were linked to adipic acid dihydrazide-agarose beads and incubated with HeLa cell nuclear protein extract. The precipitated proteins were resolved by SDS-PAGE (12%) and stained with Coomassie brilliant blue. Bands were eluted and analyzed by mass spectrometry. The identified proteins are indicated by arrows.

confirmed the binding of hnRNP F/H proteins to the wild-type sequence but not to the mutated sequence (Table 2). This, in turn, suggests that these proteins play a role in G_{12-1} -mediated splicing regulation.

G_{12-1} controls the levels of *vif*mRNA and Vif protein expression from replication-competent virus. Next we analyzed the impact of the silent but inactivating mutation of G_{12-1} on gene expression from proviral plasmids. HEK 293T cells were transiently transfected with pNL4-3 or the G_{12-1} mutant proviral plasmid pNL4-3 G_{12-1} mut, and total RNA and proteins were harvested at 48 h posttransfection. The RNAs were subjected to Northern blotting and probed with an exon 7 fragment detecting all viral mRNAs. As shown in Fig. 4A, the G_{12-1} mutation led to an increased amount of *vif*mRNA (cf. lanes wt and G_{12-1} mut). In order to quantify the G_{12-1} mutation-mediated change in *vif* mRNA levels, a quantitative real-time PCR was performed using *vif* mRNA-specific exon junction primers. As a control, we determined the amounts of all viral mRNAs by using a primer pair

TABLE 2 Results of mass spectrometric analysis of proteins of the G_{12-1} RNA pulldown experiment shown in Fig. 3

Accession no.	Protein(s)	Mascot score	Molecular mass (kDa)	pI value	Sequence coverage (%)
P31943	hnRNP H	68	49.2	5.9	23
P52597	hnRNP F	63	45.6	5.3	20
P22626	hnRNPs A2/B1	124	37.4	9.3	50




FIG 4 The silent mutation of G_{12-1} increases both *vif* mRNA and protein levels. (A) Northern blot analysis of total RNA from pNL4-3-transfected HEK 293T cells isolated at 48 h posttransfection. RNA was separated in a 1% RNA agarose gel, capillary blotted, and cross-linked on a positively charged nylon membrane and UV cross-linked. The membrane was treated with a DIG-labeled DNA fragment binding to exon 7. (B) RNA from panel A was subjected to quantitative RT-PCR analysis using an exon junction primer pair specific for *vif* mRNA (3395/3396) and for exon 7 (3387/3388) for normalization of the viral load. (C) Immunoblot analysis of proteins from transiently transfected HEK 293T cells with proviral plasmids pNL4-3 and pNL4-3 G_{12-1} mut. Proteins were separated by SDS-PAGE, blotted, and analyzed with antibodies specific to Vif and p24 as a loading control for the viral load. (D) RT-PCR analysis of total RNA isolated from panel A with primer pairs specific for the 2-kb mRNA class. The primer pairs used are indicated on the left (see Fig. 1). PCR amplicons were separated on a nondenaturing 10% polyacrylamide gel and stained with ethidium bromide. Transcript isoforms are depicted on the right. To compare the total RNA amounts, a separate RT-PCR was performed with the primer pair 3502/3503 to amplify the GAPDH sequence.

amplifying exon 7 sequences that are present in all viral mRNA species. In agreement with the result obtained from the Northern blot analysis, *vif* mRNA levels were upregulated 7-fold following the disruption of G_{12-1} (Fig. 4B). Furthermore, immunoblot analysis showed an increase in the amount of Vif protein expressed within transfected cells (Fig. 4C). Taken together, these results demonstrate that G_{12-1} is important for splicing regulation of 3' ss A1 and the generation of functional *vif* mRNA and confirm previous observations that an increase in 5' ss D2 usage leads to an increase in exon 2 inclusion and levels of *vif* mRNA (22). However, our results additionally show that the increase in *vif* mRNA can also be mediated by activation of D2b, which is located further downstream. These data are comparable to the concomitantly observed increase in 5' ss D3 usage and *vpr* mRNA levels (see the accompanying paper by Erkelenz et al. [81]).

To quantify the frequency of D2b usage and to identify its 3' ss targets, we performed RT-PCR analysis of total RNA isolated from HEK 293T cells transfected with pNL4-3. To also monitor the impact of the G_{12-1} inactivation on D2b usage, we included the pNL4-3 G_{12-1} mut proviral DNA and focused on transcripts that were spliced not at D2 but at D2b. In addition to the published transcript isoform, 1.2b.5.7 (29), we identified three novel D2b spliced transcript isoforms (1.2b.3.5.7, 1.2b.4.7, and 1.2b.3.4.7) covering either the Tat or the Nef ORF (Fig. 4D, 2710/3392). In addition, we identified an alternatively spliced *vif1* mRNA, 1.2E.4.7, not previously found among the Rev-independent 1.8-kb species (29). Inactivation of G_{12-1} led to the increased inclusion of exon 2b in an mRNA, 1.2b.5.7, encoding a Vif-Tat-Gp41 fusion protein. Concomitantly, there was then a reduction in the amount of the exon 3-containing transcript 1.2b.3.4.7 encoding a putative 9 amino-acid (aa)-long Vif peptide (Fig. 4D, cf. lanes wt and G_{12-1} mut). The use of a primer pair covering the 5' half of the HIV-1 genome allowed the detection of a significant amount of an mRNA 1.2b.4.7 coding for a putative 12-aa-long Vif peptide when G_{12-1} was inactivated. The levels of this transcript were below the analytical limit of detection in the wild-type context (Fig. 4D, 1544/3632). Furthermore, we observed an increased amount of *tat2* mRNA 1.2.4.7, indicating more-efficient recognition of 3' ss A1. These data are in agreement with those obtained from the subgenomic minigene constructs demonstrating that G_{12-1} acts to repress 3' ss A1 recognition. In conclusion, these data support the hypothesis that 5' ss D2b, which is negatively regulated by G_{12-1} , might safeguard D2 with respect to its exon-bridging function, thus supporting 3' ss A1 activation and maintaining Vif protein levels.

G_{12-1} in intron 2 is necessary for efficient virus replication in nonpermissive cells. Since the Vif protein level was considerably increased upon the inactivation of G_{12-1} (Fig. 4C), we wanted to analyze the impact of this SRE on multiround HIV-1 replication in the presence and absence of A3G. Therefore, we produced virus by transient transfection of HEK 293T cells with the proviral plasmid pNL4-3 or its mutant derivative NL4-3 G_{12-1} mut and harvested virus-containing supernatants at 48 h posttransfection. pNL4-3 Δvif proviral DNA (64) served as a control for a *vif*-deficient virus. To monitor virus replication, the permissive host cell line CEM-SS lacking A3G (5) and the nonpermissive A3G-expressing CEM-A cell line (65) were infected with equal amounts of p24 CA (multiplicity of infection [MOI], 0.01). The heterogeneous A3G-expressing cell line CEM-T4 was also infected to analyze the replication ability of G_{12-1} mutant virus under semipermissive host cell restriction pressure conditions (66). The A3G expression levels of all three cell lines were determined by immunoblot analysis (Fig. 5B). Cell culture supernatants were harvested at different time points after infection, and p24 capsid protein (CA) was monitored by immunoblotting (Fig. 5C) and quantified by capture ELISA (Fig. 5A) to record virus replication.

As expected, in A3G-deficient CEM-SS cells, the presence of Vif was not required for efficient virus particle production, as neither inactivation of the G_{12-1} SRE nor *vif* deficiency (NL4-3 Δvif) impaired viral replication (Fig. 5A and C). On the other hand, NL4-3 Δvif was not capable to replicate in A3G-positive CEM-A cells and newly synthesized virus was not detectable, even after 12 days postinfection (dpi) (Fig. 5A). Unexpectedly, the p24 CA production of G_{12-1} mutant virus was decreased almost 5-fold despite increased Vif protein expression and a comparable reduc-




FIG 5 The G run in intron 2 is necessary for efficient virus replication in nonpermissive cells. (A) CEM-SS, CEM-T4, and CEM-A cells were infected with the NL4-3 virus or mutant derivatives (MOI, 0.01). Virus production was determined by p24 CA capture ELISA of cell-free supernatant collected at the indicated time points. (B) Immunoblot analysis showing A3G expression in CEM-SS, CEM-T4, and CEM-A cells. As a positive control, HEK 293T cells were transiently transfected with a FLAG-tagged A3G expression plasmid. (C) Immunoblot analysis of p24-CA protein in the cell-free supernatant concentrated by sucrose centrifugation at 12 dpi.

tion in p24 CA levels was observed in CEM-T4 cells. According to the semipermissiveness of the mixed cell population, Δvif mutant virus was able to replicate, but with a delay of 2 days, presumably due to viral replication in only a subset of the CEM-T4 cells. These results are in agreement with previous observations demonstrating that the amount of Vif required for optimal viral replication is in a narrow range and that higher levels of Vif decrease viral in-

fectivity, perhaps by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site (11). To further characterize the impact of G₁₂-1 on viral replication, we assayed HIV infection of human peripheral blood mononuclear cells (PBMCs) from two healthy donors with an MOI of 0.5. In cells from both donors inactivation of G₁₂-1 caused a moderate increase in virus replication (Fig. 6A). As expected, HIV-1 Δvif did not replicate in the PBMC cultures (Fig. 6A and C). Interestingly, the activated PBMCs showed higher expression of A3G than the CEM-A and CEM-T4 cells did (Fig. 6B).

In summary, these results demonstrate the impact of G₁₂-1 as a




FIG 6 Inactivation of G₁₂-1 enhances virus replication in PBMCs. (A) PBMCs were infected with the NL4-3 virus or mutant derivatives (MOI, 0.5). Virus production was determined by p24 CA capture ELISA of cell-free supernatant collected at the indicated time points. (B) Immunoblot analysis showing A3G expression in CEM-SS, CEM-T4, and CEM-A cells and PBMCs of two human donors. αTUB, antitubulin antibody. (C) Immunoblot analysis of p24-CA protein in cell-free supernatant at 12 dpi.




FIG 7 NGS analysis reveals usage of alternative 5' ss D2b. Total RNA of HIV-1 NL4-3-infected Jurkat cells was isolated and subjected to NGS analysis. The resulting 101-nt sequence reads were mapped to the HIV-1 exon junction database, and the relative usage of every splice site was estimated. Read sequences that mapped to more than one exon junction were excluded from quantification. Shown is the relative splice site usage in samples obtained at 24 and 144 hpi.

TABLE 3 Percentages of spliced and unspliced reads obtained from HIV-1 infected T cells mapped to exon junction database

5'ss	24 hpi ^a			144 hpi ^b		
	Total no. of reads	% Spliced	% Unspliced	Total no. of reads	% Spliced	% Unspliced
D1	28	60.7	39.3	1,852	61.1	38.9
D1a	0	0.0	0.0	0	0.0	0.0
D2	31	12.9	87.1	3,401	5.3	94.7
D2b	38	0.0	100	3,919	0.2	99.8
D3	33	6.1	93.9	2,669	6.7	93.3
D4	78	53.8	46.2	4,501	27.2	72.8
D5	0	0.0	0.0	0	0.0	0.0

^a MOI, 0.1.^b MOI, 0.01.

critical SRE to maintain the balanced *vif* mRNA levels necessary for optimal HIV-1 replication in nonpermissive cells and that an appropriate ratio of Vif to A3G protein levels is required for optimal virus replication under different physiological environments.

NGS analysis of NL4-3-infected Jurkat T cells reveals that 5'ss D2b is used, albeit with low efficiency. Since we observed 5'ss D2b usage in pNL4-3-transfected HEK 293T cells, we were interested in the frequency of D2b-containing exon junctions during the course of T cell infection. Therefore, we analyzed splice site selection by RNA deep sequencing of NL4-3-infected Jurkat T cells. Total RNAs from uninfected and HIV-1-infected Jurkat T cells were isolated at 24 (MOI, 0.1) and 144 (MOI, 0.01) h postinfection (hpi), and cDNA libraries were created from poly(A)-selected mRNAs and subjected to NGS analysis. Using the Illumina sequencing protocol, we obtained ~170 million 101-nt reads per sample and mapped them to an HIV-1 exon junction database. Whereas, D2b usage was not detectable at 24 hpi, most likely due to a low number of overall exon junction reads, at 144 hpi, D2b was used in 0.2% of the reads that were mapped to this genomic region (Fig. 7 and Table 3). Since we could not map any reads to an exon junction using D1a or D5 (both of which were not expected to be used [67, 68]), D2b usage should be classified as an additional alternative HIV-1 5'ss. Thus, one or several of the alternative D2b spliced transcripts may encode an additional, as yet unidentified, HIV-1 protein or protein isoform.

Newly identified D2b-derived transcripts coding for Rev and Gp41 isoforms. Since we identified D2b-A2, D2b-A3, D2b-A4b, and D2b-A5 exon junction reads (Table 4), we aimed at identifying those transcript isoforms covering these junctions. Therefore, total RNA of NL4-3-infected Jurkat cells (144 hpi) was isolated

and reverse transcribed and the resulting cDNAs were subsequently amplified with primers located immediately upstream of the *vif* ATG codon (4355) and downstream of SA7 (3392). By cloning and sequencing, we identified three cDNAs coding for new proteins, Rev4b, Gp41a, and Gp41b, all carrying 6 aa derived from Vif (MENRWQ) at their N termini (Fig. 1E).

To answer the question of whether the Gp41 isoforms could be detected in infected cells, C8166 T cells were infected with wild-type NL4-3 and NL4-3 Env-Tr712 with a stop codon at position 713 in Env employing vesicular stomatitis virus G-protein-pseudotyped virions as previously described (62, 69). HEK 293T cells were transfected with an expression vector coding for the larger Gp41 isoform, i.e., Gp41b, and the protein lysates of the infected and transfected cells were subjected to immunoblotting employing Chessie 8 antibodies directed against the C-terminal domain of Gp41 (61, 62). As expected, Gp160 and Gp41 were detected in the lysate of pNL-4-3-infected cells (Fig. 8B) but absent from the lysates of cells infected with pNL-Env-Tr712 virions encoding truncated Env lacking the Chessie 8 epitope. However, in both cases, additional reactive protein entities, with sizes ranging from approximately 13 to 23 kDa, were detected. These were absent from lysates of mock-transfected cells or when unrelated antibodies were used (not shown), meaning that they represent novel, currently undefined, proteins containing the HIV Chessie 8 epitope. Expression of the larger Gp41 isoform led to the generation of a band comparable in size to one of the Env-CT variants detectable in infected T cells (Fig. 8B). This could mean that this comigrating protein band in the infected T cells corresponds to the cloned Gp41 isoform but, in the absence of mass spectrometric identification, this remains only a postulate.

Rev4b mediates Rev-dependent luciferase expression. In order to compare the activities of Rev4b and Rev, we measured their abilities to mediate luciferase expression. HeLa-T4⁺ cells were cotransfected with the Rev-dependent luciferase reporter SVtat⁻rev⁻envRL and increasing amounts of the expression plasmids coding for Rev4b or Rev (Fig. 9). When HeLa-T4⁺ cells were transfected with the same amount of expression plasmid Rev or Rev4b, the latter yielded 2-fold higher luciferase activity (Fig. 9C), suggesting that the N-terminal amino acids of Rev4b resulted in higher protein activity. Alternatively, the better match of the AUG nucleotide surrounding of *vif* with the Kozak consensus sequence may be more efficiently recognized than that of *rev*, thus leading to a greater amount of Rev4b protein. We thus repeated the luciferase assay with Rev4b and Rev expression plasmids with identical AUG nucleotide surroundings. As shown in Fig. 8B and C, equalization of the AUG nucleotide surroundings of both the *rev4b* and

TABLE 4 5'ss D2b-derived exon junctions, transcripts, and ORFs identified in this work

Junction	Exon	No. of reads	cDNA	Transcript	Length (bp)	Protein (molecular mass [kDa])	Length (aa)
D2b_A2	1.2b.3.7	9	Identified		27	Short ORF	9
D2b_A3	1.2b.4.7	9	Identified		33	Short ORF	11
D2b_A4c	1.2b.4c.7	ND ^a	ND		24	Short ORF	8
D2b_A4a	1.2b.4a.7	ND	Identified		27	Short ORF	9
D2b_A4b	1.2b.4b.7	2	Identified	<i>rev4b</i>	376	Rev4b (14.21)	125
D2b_A7	1.2b.7	ND	Identified	<i>gp41</i> 1	432	Gp41a (16.93)	144
D2b_A5	1.2b.5.7	4	Identified	<i>gp41</i> 2	501	Gp41b (19.32)	167

^a ND, none detected.




FIG 8 Sequence alignment of authentic Gp41 and D2b-derived isoforms Gp41a and Gp41b. From position 208, all of the protein isoforms show sequence identity. (B) Western blot analysis with Gp41-CT antibodies employing lysates of cells transfected or infected with the indicated constructs. The positions of molecular mass markers are shown on the right, and those of the provirally expressed Env-CT-containing proteins are shown on the left. The Env-CT bands are a group of specifically detected low-molecular-mass protein entities.

rev ORFs resulted in equally strong luciferase expression (Fig. 9B and C), demonstrating functional equivalence of Rev4b and Rev protein isoforms in this assay.

DISCUSSION

In this study, we have performed a mutational analysis of the G runs located in the HIV-1 NL4-3 intron 2 sequence and demonstrated that *vif* mRNA splicing is tightly regulated by the intronic

G run G₁₂-1 that is localized at nt 73 to 76. So far, only the GGGG motif overlapping 5'ss D2 from its intronic position has been shown to have splicing regulatory activity by repressing exon 2 splicing (22). Here we have discovered that the hnRNP family members F/H bound to G₁₂-1 and acted on *vif* mRNA expression levels through repression of the alternative 5'ss, termed D2b. Whereas the importance of the functional strength of 5'ss D2 for *vif* expression has already been demonstrated by up and down




FIG 9 The usage of alternative 5'ss D2b allows the translation of a novel functional Rev protein variant by using the *vif* AUG. (A) Schematic drawing of the Rev-dependent luciferase reporter SVtat⁻ rev⁻ envRL. The 5'ss and 3'ss D4 and A7 are indicated. The RRE is represented by an open box. SV40early, SV40 early promoter; p(A), SV40 polyadenylation signal. (B) HeLa-T4⁺ cells were transiently transfected with pGL3-Control and cDNA expression vectors as indicated. Rev activity was quantified by *Renilla* luciferase activity and normalized to firefly luciferase activity. (C) The same as in panel B but with 1 μg expression plasmid. (D) Alignment of Rev and Rev4b sequences.




FIG 10 Splicing regulatory model for *G*₁₂₋₁. (A) Splicing at 5's D2 and D2b and 3'ss A1 and processing of *vif* mRNA are modulated by the formation of bridging interactions across exons 2 and 2b. SRSF1-dependent heptameric ESEs M1 and M2 (ESEM1/2) and SRSF4-dependent ESE Vif (ESE-Vif) facilitate the recognition of exon 2. The intronic G runs GGGG and *G*₁₂₋₁ negatively regulate exon 2 and 2b inclusion and levels of *vif* mRNA. (B) Inactivation of *G*₁₂₋₁ increased the usage of 5's D2b and facilitated the recognition of 3'ss A1. The increased usage of the intrinsically weak 5's D2b in the absence of *G*₁₂₋₁ could be due to the wide-range effect of SR proteins located upstream (X) and/or downstream (Y) of 5's D2b. Py tract, polypyrimidine tract.

mutations of its intrinsic strength (22, 70), as well as by the identification of SRE elements in exon 2 (18, 22), the inactivation of *G*₁₂₋₁ now confirms that it is the functional strength of the exon 2 or/and 2b 5'ss that regulates *vif* mRNA expression levels.

Mutation of *G*₁₂₋₁ abrogated hnRNP F/H binding and relieved silencing of the downstream alternative 5'ss D2b that led to the emergence of several viral mRNA isoforms, including an exon formed by 3'ss A1 and 5'ss D2b. However, mutation of *G*₁₂₋₁ also increased the levels of *vif* mRNA, suggesting that an increase in 5'ss D2b recognition might also parallel an enhanced formation of exon definition complexes and thus enhanced 3'ss A1 usage. Indeed, endowing viral 5'ss D2 or D4 with a higher complementarity to the cellular U1 snRNA facilitates activation of the upstream 3'ss A1 and A5 (22, 24). Furthermore, coexpression of fully complementary U1 snRNAs directed against either 5'ss D2 or D3 (71) strongly enhances the usage of the respective upstream 3'ss A1 or A2, which is evident by high levels of *vif* and *vpr* mRNAs. Therefore, it appears likely that inactivation of *G*₁₂₋₁ promotes the recruitment of the U1 snRNP to 5'ss D2b and enhances the formation of exon definition complexes leading to both increased inclusion of exon 2b in the different viral mRNA species and higher levels of *vif* mRNA.

G runs mediate splicing regulation throughout evolution by multiple mechanisms, depending on their position relative to the splice site, distance, sequence context, and complex interactions with other splicing factors (72, 73). Therefore, the proper position of the G run seems to be decisive for its acting either as a silencer or as an enhancer. Thus, the position of *G*₁₂₋₁, i.e., downstream of 5'ss D2 but upstream of D2b, seems to be a key factor rendering it a negative regulator of *vif* mRNA by repressing 5'ss D2b.

Analyses of the hydrogen bonding patterns of U1 snRNA binding (63; http://www.uni-duesseldorf.de/rna/html/hbond_score.php) and maximum-entropy estimation (45; http://genes.mit.edu/burgelab/maxent/Xmaxentseq_scoreseq.html) revealed that the alternative 5'ss D2b was, in fact, intrinsically stronger (HBond score, 12.4; MaxEnt score, 5.99) than the upstream 5'ss D2 (HBond score, 10.7; MaxEnt score, 5.73). Thus, according to their intrinsic strength, the usage of D2b would be expected to be more frequent. However, quite on the contrary, by RNA deep sequencing of HIV-1-infected T cells, we found 26.5-fold less D2b- than D2-containing exon junction reads (a relative D2b usage of 0.2% versus a relative D2 usage of 5.3%, i.e., a 26.5-fold difference). Even though D2b usage was underrepresented in the pool of exon junction reads (Table 4) and not found in a recent transcriptome analysis by the Katze laboratory (74), it appears from our results unlikely that it is the result of mere "biological noise." We rather favor the view that it is a bona fide NL4-3 alternative 5'ss. This assumption is based on the finding that, unlike 5'ss D2b-containing exon junction reads, D1a-containing exon junction reads could not be detected in our analysis, which is compatible with the observation that 5'ss D1a appears to be tightly repressed and only infrequently used *in vivo* (68). Moreover, the usage of 5'ss D2b could be confirmed by RT-PCR, which revealed the existence of several D2b-derived transcripts when a forward primer positioned between D2 and D2b was used. Thus, the repression of D2b appears to result from the silencing activity mediated by G run *G*₁₂₋₁, which concomitantly has an indirect enhancing activity in favor of the intrinsically weaker D2 5'ss. These results also demonstrated that the functional strength of a 5'ss D2b is not only determined by its intrinsic strength, i.e., its

complementarity to the 5' end of U1 snRNA (63, 75), but also is controlled by specific SREs.

The data demonstrated in this and previous work (18, 22) suggested that splicing at 3' ss A1 and processing of *vif* mRNA are modulated by the formation of bridging interactions across exons 2 and 2b, respectively (Fig. 10). On the one hand, two SREs within the noncoding leader exon 2 enhance its splice site recognition (the SRSF1 [SF2/ASF]-dependent heptameric ESEs M1 and M2 [18] and the SRSF4 [SRp75]-dependent ESE Vif [22]). On the other hand, the intronic G run GGGG, which overlaps 5' ss D2 [22], and G_{12} -1 negatively regulate exon 2 and 2b inclusion and levels of *vif* mRNA. Mechanistically, the repressing capacity of such G runs, which overlap the 11 nt of a 5' ss, is likely based on the restricted accessibility of the U1 snRNA due to competing binding of hnRNP F/H (76). From its position upstream of 5' ss D2b, G_{12} -1 could negatively regulate the bridging interaction across exon 2b by inhibiting the usage of 5' ss D2b. In line with this, inactivation of G_{12} -1 increased the usage of 5' ss D2b and, as a result, disproportionately facilitated 3' ss A1 recognition. The inhibition could be a result of the interaction of hnRNP F/H proteins with components of the spliceosome at various steps. The influence of G runs on the progression on the spliceosomal cycle has been observed for the major myelin proteolipid protein and its isoform DM20 lacking the alternatively spliced exon 3B. Here, G run G1M2 promoted the ATP-independent formation of the E complex, which initiates the spliceosomal cycle (73). In contrast, the S3 G run of HIV-1 *tat* exon 1 promotes ATP-dependent spliceosomal A-complex formation but had no effect on E-complex formation (30). Regarding this, recent studies demonstrated that the SRE-mediated binding of the U1 snRNP to a 5' ss does not necessarily imply processing into the spliceosomal A-complex formation, but can lead to a "dead-end" complex formation that prevents the splicing process (25–28). One can imagine that such a mechanism could be responsible for the formation of *vif* mRNA when 3' ss A1 is recognized by cross-exon interactions, which seems to be facilitated by the binding of U1 snRNP to the 5' ss without splicing at this position. For further information, see the accompanying paper by Erkelenz et al. (81).

The importance of G_{12} -1 in the regulation of appropriate *vif* expression levels maintaining optimal viral replication in A3G-deficient, as well as A3G-expressing, cells was shown by multiround infection experiments in cell lines, as well as PBMCs from healthy donors. An appropriate ratio of Vif-to-A3G protein levels was required for optimal virus replication, and this ratio was highly dependent on the physiological environment. In accordance with the observations by Strebel and coworkers (11), Vif may function at very low levels when restriction pressure, i.e., A3G expression, is also low, whereas higher Vif levels negatively affect viral replication (Fig. 5). However, as seen in PBMCs, much higher Vif levels were required for efficient viral replication, when the host cell restriction pressure was high (Fig. 6). Thus, the higher levels of Vif due to the inactivated G_{12} -1 facilitated viral replication in the presence of large amounts of A3G. Since the expression of splicing regulatory proteins changes during the course of the infection (77), the presence of multiple SREs may be required to optimize the amount of Vif protein in different cell types or at various phases of the infection.

ACKNOWLEDGMENTS

We are grateful to Björn Wefers and Thorsten Wachtmeister for excellent technical assistance. T.W. prepared the DNA libraries and performed the

quality control for NGS DNA analysis. We thank Nathaniel R. Landau for providing pNL4-3 Δ *vif* (64).

These studies were funded by the DFG (SCHA 909/3-1), the Heinz Ansmann Foundation for AIDS Research, Düsseldorf, Germany (H.S.), and the Jürgen Manchot Stiftung (M.W., A.K., C.M., H.S.). C.M. is supported by the Heinz Ansmann Foundation for AIDS Research. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: CEM-T4 (catalog no. 117) from J. P. Jacobs (78), CEM-SS (catalog no. 776) from Peter L. Nara (78–80), CEM-A cells from Mark Wainberg and James McMahon, HIV-1_{HXB2} Vif antiserum from Dana Gabuzda (58), HIV-1_{NL4-3} Vpr antiserum (1-46) from Jeffrey Kopp, and anti-ApoC17 antibody from Klaus Strebel.

REFERENCES

- Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez-Sesma A, Rutsch F, Simon V, König R, Flory E. 2011. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. *PLoS Pathog.* 7:e1002425.
- Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye J, Crow YJ, Taylor IA, Webb M. 2011. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. *Nature* 480:379–382.
- Kirchhoff F. 2010. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. *Cell Host Microbe* 8:55–67.
- Laguette N, Sobhian B, Casartelli N, Ringgaard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature* 474:654–657.
- Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* 418:646–650.
- Coticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. *Mol. Biol. Evol.* 22:367–377.
- Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. *Genomics* 79:285–296.
- Münk C, Willemsen A, Bravo IG. 2012. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. *BMC Evol. Biol.* 12:71.
- Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? *Trends Biochem Sci.* 32:118–128.
- Wissing S, Galloway NL, Greene WC. 2010. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. *Mol. Aspects Med.* 31:383–397.
- Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K. 2004. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. *J. Biol. Chem.* 279:12355–12362.
- Jäger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. *Nature* 481:365–370.
- Clerc I, Laverdure S, Torresilla C, Landry S, Borel S, Vargas A, Arpin-Andre C, Gay B, Briant L, Gross A, Barbeau B, Mesnard JM. 2011. Polarized expression of the membrane ASP protein derived from HIV-1 antisense transcription in T cells. *Retrovirology* 8:74.
- Wahl MC, Will CL, Luhrmann R. 2009. The spliceosome: design principles of a dynamic RNP machine. *Cell* 136:701–718.
- Michaud S, Reed R. 1991. An ATP-independent complex commits pre-mRNA to the mammalian spliceosome assembly pathway. *Genes Dev.* 5:2534–2546.
- Hoffman BE, Grabowski PJ. 1992. U1 snRNP targets an essential splicing

- factor, U2AF65, to the 3' splice site by a network of interactions spanning the exon. *Genes Dev.* 6:2554–2568.
17. Robberson BL, Cote GJ, Berget SM. 1990. Exon definition may facilitate splice site selection in RNAs with multiple exons. *Mol. Cell. Biol.* 10:84–94.
 18. Kammler S, Otte M, Hauber I, Kjems J, Hauber J, Schaal H. 2006. The strength of the HIV-1 3' splice sites affects Rev function. *Retrovirology* 3:89.
 19. Cullen BR. 2003. Nuclear mRNA export: insights from virology. *Trends Biochem Sci.* 28:419–424.
 20. Hoffmann D, Schwarck D, Banning C, Brenner M, Mariyanna L, Krepstakies M, Schindler M, Millar DP, Hauber J. 2012. Formation of trans-activation competent HIV-1 Rev:RRE complexes requires the recruitment of multiple protein activation domains. *PLoS One* 7:e38305.
 21. Pollard VW, Malim MH. 1998. The HIV-1 Rev protein. *Annu. Rev. Microbiol.* 52:491–532.
 22. Exline CM, Feng Z, Stoltzfus CM. 2008. Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 *vif* gene expression. *J. Virol.* 82:3921–3931.
 23. Mandal D, Exline CM, Feng Z, Stoltzfus CM. 2009. Regulation of *Vif* mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G. *J. Virol.* 83:6067–6078.
 24. Asang C, Hauber I, Schaal H. 2008. Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancer. *Nucleic Acids Res.* 36:1450–1463.
 25. Domsic JK, Wang Y, Mayeda A, Krainer AR, Stoltzfus CM. 2003. Human immunodeficiency virus type 1 hnRNP A/B-dependent exonic splicing silencer ESSV antagonizes binding of U2AF65 to viral polypyrimidine tracts. *Mol. Cell. Biol.* 23:8762–8772.
 26. Motta-Mena LB, Smith SA, Mallory MJ, Jackson J, Wang J, Lynch KW. 2011. A disease-associated polymorphism alters splicing of the human CD45 phosphatase gene by disrupting combinatorial repression by heterogeneous nuclear ribonucleoproteins (hnRNPs). *J. Biol. Chem.* 286:20043–20053.
 27. Sharma S, Kohlstaedt LA, Damianov A, Rio DC, Black DL. 2008. Polypyrimidine tract binding protein controls the transition from exon definition to an intron defined spliceosome. *Nat. Struct. Mol. Biol.* 15: 183–191.
 28. Sharma S, Maris C, Allain FH, Black DL. 2011. U1 snRNA directly interacts with polypyrimidine tract-binding protein during splicing repression. *Mol. Cell* 41:579–588.
 29. Purcell DF, Martin MA. 1993. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. *J. Virol.* 67:6365–6378.
 30. Schaub MC, Lopez SR, Caputi M. 2007. Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes. *J. Biol. Chem.* 282:13617–13626.
 31. Caputi M, Zahler AM. 2001. Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H'/F/2H9 family. *J. Biol. Chem.* 276:43850–43859.
 32. Carlo T, Sterner DA, Berget SM. 1996. An intron splicing enhancer containing a G-rich repeat facilitates inclusion of a vertebrate micro-exon. *RNA* 2:342–353.
 33. Chen CD, Kobayashi R, Helfman DM. 1999. Binding of hnRNP H to an exonic splicing silencer is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene. *Genes Dev.* 13:593–606.
 34. Del Gatto F, Breathnach R. 1995. Exon and intron sequences, respectively, repress and activate splicing of a fibroblast growth factor receptor 2 alternative exon. *Mol. Cell. Biol.* 15:4825–4834.
 35. Marcucci R, Baralle FE, Romano M. 2007. Complex splicing control of the human thrombopoietin gene by intronic G runs. *Nucleic Acids Res.* 35:132–142.
 36. McCarthy EM, Phillips JA, III. 1998. Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. *Hum. Mol. Genet.* 7:1491–1496.
 37. McCullough AJ, Berget SM. 1997. G triplets located throughout a class of small vertebrate introns enforce intron borders and regulate splice site selection. *Mol. Cell. Biol.* 17:4562–4571.
 38. McCullough AJ, Berget SM. 2000. An intronic splicing enhancer binds U1 snRNPs to enhance splicing and select 5' splice sites. *Mol. Cell. Biol.* 20:9225–9235.
 39. Chou MY, Rooke N, Turck CW, Black DL. 1999. hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells. *Mol. Cell. Biol.* 19:69–77.
 40. Garneau D, Revil T, Fiset JF, Chabot B. 2005. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. *J. Biol. Chem.* 280:22641–22650.
 41. Han K, Yeo G, An P, Burge CB, Grabowski PJ. 2005. A combinatorial code for splicing silencing: UAGG and GGGG motifs. *PLoS Biol.* 3:e158.
 42. Hastings ML, Wilson CM, Munroe SH. 2001. A purine-rich intronic element enhances alternative splicing of thyroid hormone receptor mRNA. *RNA* 7:859–874.
 43. Min H, Chan RC, Black DL. 1995. The generally expressed hnRNP F is involved in a neural-specific pre-mRNA splicing event. *Genes Dev.* 9:2659–2671.
 44. Xiao X, Wang Z, Jang M, Nutiu R, Wang ET, Burge CB. 2009. Splice site strength-dependent activity and genetic buffering by poly-G runs. *Nat. Struct. Mol. Biol.* 16:1094–1100.
 45. Yeo G, Burge CB. 2004. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J. Comput. Biol.* 11:377–394.
 46. Zhang XH, Leslie CS, Chasin LA. 2005. Computational searches for splicing signals. *Methods* 37:292–305.
 47. Jablonski JA, Caputi M. 2009. Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity. *J. Virol.* 83:981–992.
 48. Lund N, Milev MP, Wong R, Sanmuganatham T, Woolaway K, Chabot B, Abou Elela S, Moulard AJ, Cochrane A. 2012. Differential effects of hnRNP D/AUF1 isoforms on HIV-1 gene expression. *Nucleic Acids Res.* 40:3663–3675.
 49. Jacquenet S, Mereau A, Bilodeau PS, Damier L, Stoltzfus CM, Branlant C. 2001. A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. *J. Biol. Chem.* 276:40464–40475.
 50. Caputi M, Zahler AM. 2002. SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D. *EMBO J.* 21:845–855.
 51. Asang C, Erkelenz S, Schaal H. 2012. The HIV-1 major splice donor D1 is activated by splicing enhancer elements within the leader region and the p17-inhibitory sequence. *Virology* 432:133–145.
 52. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. *J. Virol.* 59:284–291.
 53. Singh KK, Erkelenz S, Rattay S, Dehof AK, Hildebrandt A, Schulze-Osthoff K, Schaal H, Schwerk C. 2010. Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold. *RNA* 16:2442–2454.
 54. Krummheuer J, Lenz C, Kammler S, Scheid A, Schaal H. 2001. Influence of the small leader exons 2 and 3 on human immunodeficiency virus type 1 gene expression. *Virology* 286:276–289.
 55. Selden RF, Howie KB, Rowe ME, Goodman HM, Moore DD. 1986. Human growth hormone as a reporter gene in regulation studies employing transient gene expression. *Mol. Cell. Biol.* 6:3173–3179.
 56. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156–159.
 57. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680–685.
 58. Goncalves J, Jallepalli P, Gabuzda DH. 1994. Subcellular localization of the *Vif* protein of human immunodeficiency virus type 1. *J. Virol.* 68:704–712.
 59. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. *Retrovirology* 1:27.
 60. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. *J. Virol.* 79:5870–5874.
 61. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, Lewis GK. 1994. Epitope mapping and topol-

- ogy of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. *AIDS Res. Hum. Retrovir.* 10:371–381.
62. Holtkotte D, Pfeiffer T, Bosch V. 2007. Cell-free infectivity of HIV type 1 produced in nonpermissive cells is only moderately impacted by C-terminal Env truncation despite abrogation of viral spread. *AIDS Res. Hum. Retrovir.* 23:729–740.
 63. Freund M, Asang C, Kammler S, Konermann C, Krummheuer J, Hipp M, Meyer I, Gierling W, Theiss S, Preuss T, Schindler D, Kjems J, Schaal H. 2003. A novel approach to describe a U1 snRNA binding site. *Nucleic Acids Res.* 31:6963–6975.
 64. Mariani R, Chen D, Schrofelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. *Cell* 114:21–31.
 65. Tremblay M, Sullivan AK, Rooke R, Geleziunas R, Tsoukas C, Shematek G, Gilmore N, Wainberg MA. 1989. New CD4(+) cell line susceptible to infection by HIV-1. *J. Med. Virol.* 28:243–249.
 66. Haché G, Harris RS. 2009. CEM-T4 cells do not lack an APOBEC3G cofactor. *PLoS Pathog.* 5:e1000528.
 67. Benko DM, Schwartz S, Pavlakis GN, Felber BK. 1990. A novel human immunodeficiency virus type 1 protein, *tev*, shares sequences with *tat*, *env*, and *rev* proteins. *J. Virol.* 64:2505–2518.
 68. Lützelberger M, Reinert LS, Das AT, Berkhout B, Kjems J. 2006. A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability. *J. Biol. Chem.* 281:18644–18651.
 69. Wilk T, Pfeiffer T, Bosch V. 1992. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. *Virology* 189:167–177.
 70. Madsen JM, Stoltzfus CM. 2006. A suboptimal 5' splice site downstream of HIV-1 splice site A1 is required for unspliced viral mRNA accumulation and efficient virus replication. *Retrovirology* 3:10.
 71. Mandal D, Feng Z, Stoltzfus CM. 2010. Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs. *J. Virol.* 84:12790–12800.
 72. Voelker RB, Erkelenz S, Reynoso V, Schaal H, Berglund JA. 2012. Frequent gain and loss of intronic splicing regulatory elements during the evolution of vertebrates. *Genome Biol Evol.* 4:659–674.
 73. Wang E, Mueller WF, Hertel KJ, Cambi F. 2011. G run-mediated recognition of proteolipid protein and DM20 5' splice sites by U1 small nuclear RNA is regulated by context and proximity to the splice site. *J. Biol. Chem.* 286:4059–4071.
 74. Chang ST, Sova P, Peng X, Weiss J, Law GL, Palermo RE, Katze MG. 2011. Next-generation sequencing reveals HIV-1-mediated suppression of T cell activation and RNA processing and regulation of noncoding RNA expression in a CD4⁺ T cell line. *mBio* 2(5):e00134–11. doi:10.1128/mBio.00134-11.
 75. Kammler S, Leurs C, Freund M, Krummheuer J, Seidel K, Tange TO, Lund MK, Kjems J, Scheid A, Schaal H. 2001. The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. *RNA* 7:421–434.
 76. Buratti E, Baralle M, De Conti L, Baralle D, Romano M, Ayala YM, Baralle FE. 2004. hnRNP H binding at the 5' splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSHbeta genes. *Nucleic Acids Res.* 32:4224–4236.
 77. Dowling D, Nasr-Esfahani S, Tan CH, O'Brien K, Howard JL, Jans DA, Purcell DF, Stoltzfus CM, Sonza S. 2008. HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. *Retrovirology* 5:18.
 78. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE. 1965. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. *Cancer* 18:522–529.
 79. Nara PL, Hatch WC, Dunlop NM, Robey WG, Fischinger PJ. 1987. Simple, rapid quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. *AIDS Res. Hum. Retroviruses* 3:283–302.
 80. Nara PL, Fischinger PJ. 1988. Quantitative infectivity assay for HIV-1 and -2. *Nature* 332:469–470.
 81. Erkelenz S, Poschmann G, Theiss S, Stefanski A, Hillebrand F, Otte M, Stühler K, Schaal H. 2013. Tra2-mediated recognition of HIV-1 5' splice site D3 as a key factor in the processing of *vpr* mRNA. *J. Virol.* 87:2721–2734.